Anavex Life Sciences Corp. Company Profile (NASDAQ:AVXL)

About Anavex Life Sciences Corp. (NASDAQ:AVXL)

Anavex Life Sciences Corp. logoAnavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company's lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer's disease and other central nervous system (CNS) diseases. The Company's SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer's disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AVXL
  • CUSIP: N/A
  • Web: www.anavex.com
Capitalization:
  • Market Cap: $184.71 million
  • Outstanding Shares: 42,172,000
Average Prices:
  • 50 Day Moving Avg: $4.52
  • 200 Day Moving Avg: $4.52
  • 52 Week Range: $2.43 - $6.30
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: Infinity
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.56 per share
  • Price / Book: 7.73
Profitability:
  • EBIDTA: ($15,610,000.00)
  • Return on Equity: -95.68%
  • Return on Assets: -84.88%
Debt:
  • Current Ratio: 17.14%
  • Quick Ratio: 17.14%
Misc:
  • Average Volume: 323,967 shs.
  • Beta: 0.77
  • Short Ratio: 14.9
 

Frequently Asked Questions for Anavex Life Sciences Corp. (NASDAQ:AVXL)

What is Anavex Life Sciences Corp.'s stock symbol?

Anavex Life Sciences Corp. trades on the NASDAQ under the ticker symbol "AVXL."

How were Anavex Life Sciences Corp.'s earnings last quarter?

Anavex Life Sciences Corp. (NASDAQ:AVXL) posted its earnings results on Monday, August, 7th. The company reported ($0.09) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.09). View Anavex Life Sciences Corp.'s Earnings History.

When will Anavex Life Sciences Corp. make its next earnings announcement?

Anavex Life Sciences Corp. is scheduled to release their next quarterly earnings announcement on Monday, December, 11th 2017. View Earnings Estimates for Anavex Life Sciences Corp..

Where is Anavex Life Sciences Corp.'s stock going? Where will Anavex Life Sciences Corp.'s stock price be in 2017?

3 analysts have issued 12-month target prices for Anavex Life Sciences Corp.'s shares. Their predictions range from $10.00 to $16.00. On average, they expect Anavex Life Sciences Corp.'s share price to reach $13.67 in the next twelve months. View Analyst Ratings for Anavex Life Sciences Corp..

What are analysts saying about Anavex Life Sciences Corp. stock?

Here are some recent quotes from research analysts about Anavex Life Sciences Corp. stock:

  • 1. According to Zacks Investment Research, "ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. " (9/18/2017)
  • 2. Maxim Group analysts commented, "Anavex announced the appointment of Andrew J. Cole, M.D., F.R.C.P.(C.) to its Scientific Advisory Board. Normally we would not comment on an advisory board addition however we are quite impressed with Dr. Cole and we believe his role represents a real element of validation to the company. Dr. Andrew J. Cole is Director of the MGH Epilepsy Service, Chief of the Division of Clinical Neurophysiology and Epilepsy and Professor of Neurology at Harvard Medical School. He graduated from Dartmouth College Magna Cum Laude and Dartmouth Medical School. He trained in Neurology and Clinical Neurophysiology at the Montreal Neurological Institute, and then moved to Johns Hopkins University School of Medicine where he was Assistant Professor of Neurology. He came to Massachusetts General Hospital in 1992 where he started and developed the MGH Epilepsy Service and founded the MGH Pediatric Epilepsy Service. He has published extensively in clinical neurology, epilepsy, clinical neurophysiology and basic neuroscience. In addition to research and clinical work, Dr. Cole lectures frequently throughout the United States and internationally, and has been a visiting professor at numerous institutions in the U.S.A. and abroad. I am impressed with Anavex and its potential CNS platform drug, ANAVEX 2-73, which has shown encouraging clinical safety data combined with promising preclinical anti-seizure data," said Andrew J. Cole, M.D., F.R.C.P.(C.), Director of the Massachusetts General Hospital Epilepsy Service and Professor of Neurology at Harvard Medical School." (7/20/2017)

Who are some of Anavex Life Sciences Corp.'s key competitors?

Who owns Anavex Life Sciences Corp. stock?

Anavex Life Sciences Corp.'s stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.91%), State Street Corp (1.43%), Northern Trust Corp (1.04%), Bank of New York Mellon Corp (0.27%), TIAA CREF Investment Management LLC (0.23%) and Teachers Advisors LLC (0.16%). View Institutional Ownership Trends for Anavex Life Sciences Corp..

Who sold Anavex Life Sciences Corp. stock? Who is selling Anavex Life Sciences Corp. stock?

Anavex Life Sciences Corp.'s stock was sold by a variety of institutional investors in the last quarter, including TIAA CREF Investment Management LLC, California State Teachers Retirement System, Bank of New York Mellon Corp and New York State Common Retirement Fund. View Insider Buying and Selling for Anavex Life Sciences Corp..

Who bought Anavex Life Sciences Corp. stock? Who is buying Anavex Life Sciences Corp. stock?

Anavex Life Sciences Corp.'s stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., State Street Corp, Northern Trust Corp, Marshall Wace North America L.P., Virtu KCG Holdings LLC, Alliancebernstein L.P., State of Wisconsin Investment Board and Edge Wealth Management LLC. View Insider Buying and Selling for Anavex Life Sciences Corp..

How do I buy Anavex Life Sciences Corp. stock?

Shares of Anavex Life Sciences Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anavex Life Sciences Corp.'s stock price today?

One share of Anavex Life Sciences Corp. stock can currently be purchased for approximately $4.33.


MarketBeat Community Rating for Anavex Life Sciences Corp. (NASDAQ AVXL)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  147 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  197
MarketBeat's community ratings are surveys of what our community members think about Anavex Life Sciences Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Anavex Life Sciences Corp. (NASDAQ:AVXL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.67 (215.63% upside)

Analysts' Ratings History for Anavex Life Sciences Corp. (NASDAQ:AVXL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/9/2017Noble FinancialReiterated RatingBuyHighView Rating Details
8/7/2017Maxim GroupSet Price TargetBuy$15.00LowView Rating Details
10/5/2016FBR & CoReiterated RatingOutperform$10.00N/AView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Anavex Life Sciences Corp. (NASDAQ:AVXL)
Earnings by Quarter for Anavex Life Sciences Corp. (NASDAQ:AVXL)
Earnings History by Quarter for Anavex Life Sciences Corp. (NASDAQ AVXL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/11/2017($0.10)N/AView Earnings Details
8/7/2017Q3 2017($0.09)($0.09)ViewN/AView Earnings Details
2/7/2017Q1 2017($0.08)ViewN/AView Earnings Details
8/11/2016Q316($0.09)($0.06)ViewN/AView Earnings Details
5/11/2016Q2($0.16)($0.06)ViewN/AView Earnings Details
2/8/2016Q116($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Anavex Life Sciences Corp. (NASDAQ:AVXL)
Current Year EPS Consensus Estimate: $-0.36 EPS

Dividends

Dividend History for Anavex Life Sciences Corp. (NASDAQ:AVXL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Anavex Life Sciences Corp. (NASDAQ:AVXL)
Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 24.41%
Insider Trades by Quarter for Anavex Life Sciences Corp. (NASDAQ:AVXL)
Institutional Ownership by Quarter for Anavex Life Sciences Corp. (NASDAQ:AVXL)
Insider Trades by Quarter for Anavex Life Sciences Corp. (NASDAQ:AVXL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/18/2017Christopher U MisslingInsiderBuy375$4.40$1,650.00View SEC Filing  
9/14/2017Christopher U MisslingInsiderBuy375$4.58$1,717.50View SEC Filing  
9/11/2017Christopher U MisslingInsiderBuy375$4.81$1,803.75View SEC Filing  
9/7/2017Christopher U MisslingInsiderBuy375$4.76$1,785.00View SEC Filing  
9/5/2017Christopher U MisslingInsiderBuy375$4.90$1,837.50View SEC Filing  
8/31/2017Christopher U MisslingInsiderBuy375$4.48$1,680.00View SEC Filing  
8/28/2017Christopher U MisslingInsiderBuy375$4.44$1,665.00View SEC Filing  
8/24/2017Christopher U MisslingInsiderBuy375$4.54$1,702.50View SEC Filing  
8/21/2017Christopher U MisslingInsiderBuy375$4.07$1,526.25View SEC Filing  
8/18/2017Christopher U MisslingInsiderBuy375$3.81$1,428.75View SEC Filing  
8/14/2017Christopher U MisslingInsiderBuy375$3.70$1,387.50View SEC Filing  
8/11/2017Christopher U MisslingInsiderBuy750$3.55$2,662.50View SEC Filing  
7/14/2015Christopher U MisslingCEOBuy1,000$0.52$520.00View SEC Filing  
7/13/2015Christopher U MisslingCEOBuy1,000$0.53$530.00View SEC Filing  
7/7/2015Christopher U MisslingCEOBuy2,000$0.49$980.00View SEC Filing  
7/1/2015Christopher U MisslingCEOBuy2,000$0.45$900.00View SEC Filing  
6/23/2015Christopher U MisslingCEOBuy1,000$0.47$470.00View SEC Filing  
6/22/2015Christopher U MisslingCEOBuy1,000$0.42$420.00View SEC Filing  
6/16/2015Christopher U MisslingCEOBuy1,000$0.44$440.00View SEC Filing  
6/15/2015Christopher U MisslingCEOBuy1,000$0.43$430.00View SEC Filing  
6/10/2015Christopher U MisslingCEOBuy1,000$0.36$360.00View SEC Filing  
6/8/2015Christopher U MisslingCEOBuy1,000$0.35$350.00View SEC Filing  
6/4/2015Christopher U MisslingCEOBuy1,000$0.37$370.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Anavex Life Sciences Corp. (NASDAQ:AVXL)
Latest Headlines for Anavex Life Sciences Corp. (NASDAQ:AVXL)
Source:
DateHeadline
americanbankingnews.com logoAnavex Life Sciences Corp. (AVXL) vs. Its Peers Head-To-Head Survey
www.americanbankingnews.com - September 18 at 10:30 PM
americanbankingnews.com logoAnavex Life Sciences Corp. (AVXL) Upgraded at Zacks Investment Research
www.americanbankingnews.com - September 18 at 4:34 PM
americanbankingnews.com logoAnavex Life Sciences Corp. (AVXL) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - September 15 at 4:22 PM
americanbankingnews.com logoAnavex Life Sciences Corp. (AVXL) vs. Its Competitors Head to Head Survey
www.americanbankingnews.com - September 14 at 8:20 AM
americanbankingnews.com logoContrasting Anavex Life Sciences Corp. (AVXL) and its Peers
www.americanbankingnews.com - September 9 at 10:26 AM
americanbankingnews.com logoReviewing Epirus Biopharmaceuticals (EPRS) & Anavex Life Sciences Corp. (AVXL)
www.americanbankingnews.com - September 7 at 12:06 AM
americanbankingnews.com logoAnavex Life Sciences Corp. (AVXL) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - September 6 at 8:28 PM
globenewswire.com logoAnavex Life Sciences Issued New US Patent for Composition of Matter Covering ANAVEX™ 2-73 - GlobeNewswire (press release)
globenewswire.com - September 5 at 10:53 PM
streetinsider.com logoAnavex Life Sciences (AVXL) Reports U.S. Patent for Composition of Matter Covering ANAVEX 2-73
www.streetinsider.com - September 5 at 5:49 PM
finance.yahoo.com logoAnavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX™ 2-73
finance.yahoo.com - September 5 at 5:49 PM
americanbankingnews.com logoZacks Investment Research Lowers Anavex Life Sciences Corp. (AVXL) to Hold
www.americanbankingnews.com - September 5 at 5:16 PM
americanbankingnews.com logoAffymax (AFFY) vs. Anavex Life Sciences Corp. (AVXL) Critical Analysis
www.americanbankingnews.com - September 5 at 2:22 AM
americanbankingnews.com logoAnavex Life Sciences Corp. (AVXL) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - August 28 at 4:26 PM
americanbankingnews.com logoVBI Vaccines (VBIV) versus Anavex Life Sciences Corp. (AVXL) Head to Head Comparison
www.americanbankingnews.com - August 16 at 6:32 PM
americanbankingnews.com logoAnavex Life Sciences Corp. (AVXL) Expected to Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - August 11 at 12:14 AM
thestreet.com logoInteresting AVXL Call Options For September 15th
www.thestreet.com - August 10 at 9:13 PM
americanbankingnews.com logoAnavex Life Sciences Corp. (AVXL) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - August 10 at 4:32 PM
americanbankingnews.com logoNoble Financial Reiterates "Buy" Rating for Anavex Life Sciences Corp. (NASDAQ:AVXL)
www.americanbankingnews.com - August 9 at 9:00 AM
americanbankingnews.com logoAnavex Life Sciences Corp. (AVXL) Issues Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - August 8 at 10:51 AM
globenewswire.com logoAnavex Reports Fiscal Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 7 at 10:03 PM
finance.yahoo.com logoAnavex Reports Fiscal Third Quarter 2017 Financial Results
finance.yahoo.com - August 7 at 5:01 PM
finance.yahoo.com logoAnavex Life Sciences reports 3Q loss
finance.yahoo.com - August 7 at 5:01 PM
americanbankingnews.com logoAnalyzing Anavex Life Sciences Corp. (NASDAQ:AVXL) and ContraFect Corporation (CFRX)
www.americanbankingnews.com - August 7 at 4:28 PM
americanbankingnews.com logoMaxim Group Analysts Give Anavex Life Sciences Corp. (AVXL) a $15.00 Price Target
www.americanbankingnews.com - August 7 at 1:08 PM
americanbankingnews.com logoAnavex Life Sciences Corp. (AVXL) versus Windtree Therapeutics (WINT) Head to Head Comparison
www.americanbankingnews.com - August 3 at 8:48 PM
americanbankingnews.com logoAnavex Life Sciences Corp. (AVXL) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:18 AM
americanbankingnews.com logoAnalyzing DNIB Unwind (BIND) and Anavex Life Sciences Corp. (AVXL)
www.americanbankingnews.com - July 23 at 12:08 AM
americanbankingnews.com logo Brokerages Expect Anavex Life Sciences Corp. (AVXL) to Post -$0.09 Earnings Per Share
www.americanbankingnews.com - July 21 at 6:26 PM
nasdaq.com logoNoteworthy Friday Option Activity: TOL, GME, AVXL
www.nasdaq.com - July 21 at 5:46 PM
globenewswire.com logoAnavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board - GlobeNewswire (press release)
globenewswire.com - July 20 at 5:46 PM
finance.yahoo.com logoAnavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board
finance.yahoo.com - July 20 at 5:46 PM
americanbankingnews.com logoAnavex Life Sciences Corp. (NASDAQ:AVXL) Receives "Buy" Rating from Maxim Group
www.americanbankingnews.com - July 20 at 12:16 PM
americanbankingnews.com logoAnavex Life Sciences Corp. (NASDAQ:AVXL) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - July 1 at 10:04 AM
thestreet.com logoCommit To Buy Anavex Life Sciences Corp At $5, Earn 39% Annualized Using Options - TheStreet.com
www.thestreet.com - June 28 at 4:23 PM
finance.yahoo.com logo5 Biomedical Stocks That Are Expected To Surge
finance.yahoo.com - June 27 at 3:55 PM
americanbankingnews.com logoAnavex Life Sciences Corp. (AVXL) Expected to Announce Earnings of -$0.09 Per Share
www.americanbankingnews.com - June 27 at 2:16 PM
seekingalpha.com logoAnavex Life Sciences (AVXL) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 12 at 4:48 PM
americanbankingnews.com logoAnavex Life Sciences Corp. (AVXL) Short Interest Update
www.americanbankingnews.com - June 12 at 7:20 AM
americanbankingnews.com logoAnavex Life Sciences Corp. (AVXL) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - June 8 at 4:42 PM
globenewswire.com logoAnavex Life Sciences to Present at Jefferies 2017 Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - June 5 at 1:03 PM
finance.yahoo.com logoAnavex Life Sciences to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 5 at 1:03 PM
americanbankingnews.com logo-$0.09 Earnings Per Share Expected for Anavex Life Sciences Corp. (AVXL) This Quarter
www.americanbankingnews.com - June 1 at 12:28 PM
americanbankingnews.com logoMaxim Group Reiterates $15.00 Price Target for Anavex Life Sciences Corp. (AVXL)
www.americanbankingnews.com - May 23 at 7:28 PM
streetinsider.com logoAnavex Life Sciences (AVXL) Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders - StreetInsider.com
www.streetinsider.com - May 22 at 3:43 PM
finance.yahoo.com logoAnavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome: Data Presented at Antiepileptic Drug Trials XIV 2017 Conference
finance.yahoo.com - May 22 at 9:51 AM
seekingalpha.com logoAnavex Life Sciences: 5 Reasons Why I'm Short
seekingalpha.com - May 19 at 3:41 PM
americanbankingnews.com logoAnavex Life Sciences Corp. (AVXL) Earns Buy Rating from Noble Financial
www.americanbankingnews.com - May 14 at 8:45 AM
finance.yahoo.com logoAnavex Reports Fiscal Second Quarter 2017 Financial Results
finance.yahoo.com - May 11 at 1:59 AM
globenewswire.com logoAnavex Reports Fiscal Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 10 at 9:01 AM
marketbeat.com logoAnavex Life Sciences reports 2Q loss
marketbeat.com - May 10 at 7:28 AM

Social

Chart

Anavex Life Sciences Corp. (AVXL) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff